Evidence map›Paper›PMID 25505257›Full record

Trial reportJournal of the American Society of Nephrology : JASN2015

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Sharon M Moe, Safa Abdalla, Glenn M Chertow, Patrick S Parfrey, Geoffrey A Block, Ricardo Correa-Rotter, Jürgen Floege, Charles A Herzog, Gerard M London, Kenneth W Mahaffey and 5 more

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 7 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 7 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.International journal of molecular sciences · 2020
    Pooled it
  7. Guideline
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Bone turnover markers in the management of CKD-associated osteoporosis-a European consensus.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  16. Article
  17. Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Review
  18. Article
  19. Review
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 6 countries.

Sharon M MoeIndiana University School of Medicine and Roudebush Veterans Administration Medical Center, Indianapolis, Indiana; smoe@iupui.edu.
Safa AbdallaStanford University School of Medicine, Palo Alto, California;
Glenn M ChertowStanford University School of Medicine, Palo Alto, California;
Patrick S ParfreyHealth Sciences Center, St. John's, Newfoundland, Canada;
Geoffrey A BlockDenver Nephrology, Denver, Colorado;
Ricardo Correa-RotterSalvador Zubirán National Institute of Medical Sciences and Nutrition, Mexico City, Mexico;
Jürgen FloegeUniversity Hospital RWTH Aachen, Aachen, Germany;
Charles A HerzogUniversity of Minnesota, Minneapolis, Minnesota;
Gerard M LondonManhès Hospital, Paris, France;
Kenneth W MahaffeyStanford University School of Medicine, Palo Alto, California;
David C WheelerUniversity College London, London, United Kingdom;
Bastian DehmelAmgen Inc., Thousand Oaks, California; and.
William G GoodmanAmgen Inc., Thousand Oaks, California; and.
Tilman B DrüekeFrench Institute of Health and Medical Research (INSERM) Unit 1088, Faculty of Medicine/Pharmacy, University of Picardie, Amiens, France.
Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators
Amgen (United States) · USPalo Alto University · USColorado Kidney Care · USÉcole des hautes études en sciences sociales · FRIndiana University School of MedicineInserm · FRInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXRWTH Aachen University · DEStanford University · USSt. John’s Health Sciences Centre · CAUniversity College London · GBUniversity of Minnesota System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fractures are frequent in patients receiving hemodialysis. We tested the hypothesis that cinacalcet would reduce the rate of clinical fractures in patients receiving hemodialysis using data from the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events trial, a placebo-controlled trial that randomized 3883 hemodialysis patients with secondary hyperparathyroidism to receive cinacalcet or placebo for ≤64 months. This study was a prespecified secondary analysis of the trial whose primary end point was all-cause mortality and non-fatal cardiovascular events, and one of the secondary end points was first clinical fracture event. Clinical fractures were observed in 255 of 1935 (13.2%) patients randomized to placebo and 238 of 1948 (12.2%) patients randomized to cinacalcet. In an unadjusted intention-to-treat analysis, the relative hazard for fracture (cinacalcet versus placebo) was 0.89 (95% confidence interval [95% CI], 0.75 to 1.07). After adjustment for baseline characteristics and multiple fractures, the relative hazard was 0.83 (95% CI, 0.72 to 0.98). Using a prespecified lag-censoring analysis (a measure of actual drug exposure), the relative hazard for fracture was 0.72 (95% CI, 0.58 to 0.90). When participants were censored at the time of cointerventions (parathyroidectomy, transplant, or provision of commercial cinacalcet), the relative hazard was 0.71 (95% CI, 0.58 to 0.87). Fracture rates were higher in older compared with younger patients and the effect of cinacalcet appeared more pronounced in older patients. In conclusion, using an unadjusted intention-to-treat analysis, cinacalcet did not reduce the rate of clinical fracture. However, when accounting for differences in baseline characteristics, multiple fractures, and/or events prompting discontinuation of study drug, cinacalcet reduced the rate of clinical fracture by 16%-29%.

Indexed as

AdultAgedAge FactorsCinacalcetDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesFractures, BoneHumansHyperparathyroidism, SecondaryIncidenceKidney Failure, ChronicMaleMiddle AgedNaphthalenesCinacalcetNaphthalenesCKDhemodialysishyperparathyroidismosteodystrophyrenal

Identifiers

PMID25505257
PMCPMC4446874
OpenAlexW2160374584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.